175 related articles for article (PubMed ID: 28291036)
1. Potential Mechanisms of Hematological Adverse Drug Reactions in Patients Receiving Clozapine in Combination With Proton Pump Inhibitors.
Wiciński M; Węclewicz MM; Miętkiewicz M; Malinowski B; Grześk E; Klonowska J
J Psychiatr Pract; 2017 Mar; 23(2):114-120. PubMed ID: 28291036
[TBL] [Abstract][Full Text] [Related]
2. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients.
Melkersson KI; Scordo MG; Gunes A; Dahl ML
J Clin Psychiatry; 2007 May; 68(5):697-704. PubMed ID: 17503978
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
[TBL] [Abstract][Full Text] [Related]
4. Correlation Between Serum Concentrations of N-Desmethylclozapine and Granulocyte Levels in Patients with Schizophrenia: A Retrospective Observational Study.
Smith RL; Haslemo T; Andreassen OA; Eliasson E; Dahl ML; Spigset O; Molden E
CNS Drugs; 2017 Nov; 31(11):991-997. PubMed ID: 28948574
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of proton pump inhibitors in children.
Litalien C; Théorêt Y; Faure C
Clin Pharmacokinet; 2005; 44(5):441-66. PubMed ID: 15871633
[TBL] [Abstract][Full Text] [Related]
6. Clozapine-induced agranulocytosis/granulocytopenia: mechanisms and monitoring.
Wiciński M; Węclewicz MM
Curr Opin Hematol; 2018 Jan; 25(1):22-28. PubMed ID: 28984748
[TBL] [Abstract][Full Text] [Related]
7. Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological diseases.
Huang Q; Liu Q; Yin T; Hu L; Ding H; Liu S; Jiang Y
Eur J Clin Pharmacol; 2020 Jun; 76(6):833-842. PubMed ID: 32157329
[TBL] [Abstract][Full Text] [Related]
8. Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2- and CYP3A4-selective Inhibitors.
Murray M; Zhang WV; Edwards RJ
Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):388-395. PubMed ID: 29155491
[TBL] [Abstract][Full Text] [Related]
9. Confounding factors for variation of clozapine plasma levels: drug interactions with proton pump inhibitor or infectious etiologies?
Wagner S; Varet-Legros MG; Fabre C; Montastruc JL; Bagheri H
Eur J Clin Pharmacol; 2011 May; 67(5):533-4. PubMed ID: 21057941
[No Abstract] [Full Text] [Related]
10. Effect of clozapine and olanzapine on neutrophil kinetics: implications for drug-induced agranulocytosis.
Ng W; Kennar R; Uetrecht J
Chem Res Toxicol; 2014 Jul; 27(7):1104-8. PubMed ID: 24968069
[TBL] [Abstract][Full Text] [Related]
11. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
[TBL] [Abstract][Full Text] [Related]
12. Exploring the potential effect of polypharmacy on the hematologic profiles of clozapine patients.
Shuman MD; Trigoboff E; Demler TL; Opler LA
J Psychiatr Pract; 2014 Jan; 20(1):50-8. PubMed ID: 24419309
[TBL] [Abstract][Full Text] [Related]
13. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia.
Raaska K; Neuvonen PJ
Eur J Clin Pharmacol; 2000 Nov; 56(8):585-9. PubMed ID: 11151749
[TBL] [Abstract][Full Text] [Related]
14. Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians.
Tran M; Tafreshi J; Pai RG
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):326-37. PubMed ID: 20938037
[TBL] [Abstract][Full Text] [Related]
15. Drug-drug interaction between clopidogrel and the proton pump inhibitors.
Norgard NB; Mathews KD; Wall GC
Ann Pharmacother; 2009 Jul; 43(7):1266-74. PubMed ID: 19470853
[TBL] [Abstract][Full Text] [Related]
16. Omeprazole reduces clozapine plasma concentrations. A case report.
Frick A; Kopitz J; Bergemann N
Pharmacopsychiatry; 2003 May; 36(3):121-3. PubMed ID: 12806570
[TBL] [Abstract][Full Text] [Related]
17. Effect of lemborexant on pharmacokinetics of clozapine: A potential drug-drug interaction mediated by time-dependent inhibition of CYP3A4.
Watanabe K; Misaka S; Kanno-Nozaki K; Chiyoda T; Suzuki Y; Sato A; Suto T; Kuroda J; Shimomura K; Miura I; Yabe H
Br J Clin Pharmacol; 2024 Jan; 90(1):354-359. PubMed ID: 37596710
[TBL] [Abstract][Full Text] [Related]
18. Genetic Determinants of Clozapine-Induced Metabolic Side Effects.
Vasudev K; Choi YH; Norman R; Kim RB; Schwarz UI
Can J Psychiatry; 2017 Feb; 62(2):138-149. PubMed ID: 27681143
[TBL] [Abstract][Full Text] [Related]
19. N-desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis.
Gerson SL; Arce C; Meltzer HY
Br J Haematol; 1994 Mar; 86(3):555-61. PubMed ID: 8043437
[TBL] [Abstract][Full Text] [Related]
20. The use of proton pump inhibitors in children: a comprehensive review.
Gibbons TE; Gold BD
Paediatr Drugs; 2003; 5(1):25-40. PubMed ID: 12513104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
